Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)

Trial Profile

Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 13 Nov 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 24 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top